Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 59

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 59
---
2013 Equity Incentive Plan on April 2, 2024. Vesting of these RSUs is contingent upon achievement of three share price appreciation milestones within four years of the date of grant, as well as continued employment, as described in greater detail in the “Narrative Disclosure to Summary Compensation Table” section beginning on page 31above. In accordance with SEC rules, the number of RSUs in column (i) and the value of those RSUs in column (j) reflects threshold performance assuming one share price appreciation milestone is achieved. (10) Messrs. Sawaf and Grimaud were each granted RSUs under our 2013 Equity Incentive Plan on November 1, 2021 in connection with our restructuring. 25% of these RSUs vested on November 20, 2022 and the remaining 75% of the RSUs vest in equal quarterly installments over the following three years, subject to the officer’s continuous service through each vesting date. (11) Messrs. Sawaf and Grimaud were each granted RSUs under our 2013 Equity Incentive Plan on November 1, 2021 in connection with a promotion. 25% of these RSUs vested on November 20, 2022 and the remaining 75% of the RSUs vest in equal quarterly installments over the following three years, subject to the officer’s continuous service through each vesting date. (12) Mr. Sawaf was granted RSUs under our 2013 Equity Incentive Plan on December 2, 2021 in connection with our restructuring. 25% of the RSUs vested on November 20, 2022 and the remaining 75% of the RSUs vest in equal quarterly installments over the following three years, subject to Mr. Sawaf’s continuous service through each vesting date. (13) Messrs. Sawaf and Grimaud were each granted RSUs under our 2013 Equity Incentive Plan on June 1, 2022 in connection with a promotion. 25% of the RSUs vested on May 20, 2023 and the remaining 75% of the RSUs vest in equal quarterly installments over the following three years, subject to the officer’s continuous service through each vesting date. Employment Arrangements With Named Executive Officers We have entered into offer letters with each of our named executive officers at the commencement of their employment with us, and which set forth the initial terms